The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
- PMID: 29637360
- PMCID: PMC5893740
- DOI: 10.1007/s00296-018-3977-5
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Thai language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, internal consistency, Cronbach's alpha, interscale correlations, test-retest reliability, and construct validity (convergent and discriminant validity). A total of 104 JIA patients (45.2% systemic JIA, 10.6% oligoarticular, 9.6% RF negative polyarthritis, 34.6% other categories) and 102 healthy children, were enrolled in one paediatric rheumatology centre. Notably, none of the enrolled JIA patients is affected with psoriatic arthritis or undifferentiated arthritis. The JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory psychometric performances. In conclusion, the Thai version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
Keywords: Disease status; Functional ability; Health-related quality of life; JAMAR; Juvenile idiopathic arthritis.
Conflict of interest statement
Conflict of interest
Dr. Vilaiyuk reports funding support from Istituto Giannina Gaslini, Genoa, Italy, for the data collection and translation performed at her site within the EPOCA project. Dr. Ruperto has received grants from BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer, Sobi, during the conduct of the study and personal fees and speaker honorarium from Abbvie, Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol Myers Squibb, Celgene, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rpharm, Roche, Sanofi, Servier and Takeda. Dr. Consolaro, Dr. Bovis, Dr. Lerkvaleekul, Dr. Mairiang, Dr. Pipatkullachart and Dr. Soponkanaporn have nothing to disclose.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study as per the requirement of the local ethical committee.
Similar articles
-
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).Rheumatol Int. 2018 Apr;38(Suppl 1):171-178. doi: 10.1007/s00296-018-3958-8. Epub 2018 Apr 7. Rheumatol Int. 2018. PMID: 29637366 Free PMC article.
-
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).Rheumatol Int. 2018 Apr;38(Suppl 1):203-209. doi: 10.1007/s00296-018-3952-1. Epub 2018 Apr 7. Rheumatol Int. 2018. PMID: 29637371 Free PMC article.
-
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).Rheumatol Int. 2018 Apr;38(Suppl 1):163-169. doi: 10.1007/s00296-018-3948-x. Epub 2018 Apr 7. Rheumatol Int. 2018. PMID: 29637363 Free PMC article.
-
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology.Rheumatol Int. 2018 Apr;38(Suppl 1):5-17. doi: 10.1007/s00296-018-3944-1. Epub 2018 Apr 7. Rheumatol Int. 2018. PMID: 29637323 Free PMC article. Review.
-
Measures of health status and quality of life in juvenile rheumatoid arthritis: Pediatric Quality of Life Inventory (PedsQL) Rheumatology Module 3.0, Juvenile Arthritis Quality of Life Questionnaire (JAQQ), Paediatric Rheumatology Quality of Life Scale (PRQL), and Childhood Arthritis Health Profile (CAHP).Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S438-45. doi: 10.1002/acr.20560. Arthritis Care Res (Hoboken). 2011. PMID: 22588764 Free PMC article. Review.
Cited by
-
Assessment of transition readiness in adolescents in Thailand with rheumatic diseases: a cross-sectional study.Pediatr Rheumatol Online J. 2021 Jun 30;19(1):101. doi: 10.1186/s12969-021-00602-5. Pediatr Rheumatol Online J. 2021. PMID: 34193176 Free PMC article.
References
-
- Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, Garrone M, et al. Seeking insights into the EPidemiology, treatment and outcome of childhood arthritis through a multinational collaborative effort: Introduction of the EPOCA study. Pediatr Rheumatol Online J. 2012;10(1):39. doi: 10.1186/1546-0096-10-39. - DOI - PMC - PubMed
-
- Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone E, et al. Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatol Int. 2018 - PMC - PubMed
-
- Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25(10):1991–1994. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical